124 related articles for article (PubMed ID: 30690293)
1. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
2. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
[TBL] [Abstract][Full Text] [Related]
3. Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Filleron T; Le Guellec S; Chevreau C; Cabarrou B; Lesluyes T; Lodin S; Massoubre A; Mounier M; Poublanc M; Chibon F; Valentin T
BMC Cancer; 2020 Jul; 20(1):716. PubMed ID: 32736540
[TBL] [Abstract][Full Text] [Related]
4. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
Eilber FC; Eilber FR; Eckardt J; Rosen G; Riedel E; Maki RG; Brennan MF; Singer S
Ann Surg; 2004 Oct; 240(4):686-95; discussion 695-7. PubMed ID: 15383796
[TBL] [Abstract][Full Text] [Related]
5. Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.
Schenone AD; Luo J; Montgomery L; Morgensztern D; Adkins DR; Van Tine BA
Cancer Med; 2014 Jun; 3(3):603-12. PubMed ID: 24574357
[TBL] [Abstract][Full Text] [Related]
6. High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival (RFS) After Resection of Extremity and Truncal Soft Tissue Sarcoma.
Traweek RS; Lyu HG; Witt RG; Snyder RA; Nassif EF; Krijgh DD; Smith JM; Tilney GS; Feng C; Chiang YJ; Torres KE; Roubaud MJ; Scally CP; Hunt KK; Keung EZ; Mericli AF; Roland CL
Ann Surg Oncol; 2024 Jun; 31(6):4138-4147. PubMed ID: 38396039
[TBL] [Abstract][Full Text] [Related]
7. The Combined Use of Inflammation Markers, Modified Glasgow Prognostic Score, and Sarculator Nomogram in Extremity Soft Tissue Sarcoma: A Multicenter Observational Study.
Nakamura T; Takenaka S; Outani H; Hagi T; Tamiya H; Imura Y; Asanuma K; Sudo A
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473433
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials.
Wang D; Harris J; Kraybill WG; Eisenberg B; Kirsch DG; Ettinger DS; Kane JM; Barry PN; Naghavi A; Freeman CR; Chen YL; Hitchcock YJ; Bedi M; Salerno KE; Severin D; Godette KD; Larrier NA; Curran WJ; Torres-Saavedra PA; Lucas DR
JAMA Oncol; 2023 May; 9(5):646-655. PubMed ID: 36995690
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Pizzamiglio S; Verderio P; Fontana V; Donati DM; Palassini E; Sanfilippo R; Bianchi G; Bertuzzi A; Morosi C; Pasquali S; Stacchiotti S; Bagué S; Coindre JM; Miceli R; Dei Tos AP; Casali PG
J Clin Oncol; 2024 Mar; 42(8):898-906. PubMed ID: 38232337
[TBL] [Abstract][Full Text] [Related]
10. Adherence to National Comprehensive Cancer Network Guidelines is Associated with Improved Survival for Patients with Stage 2A and Stages 2B and 3 Extremity and Superficial Trunk Soft Tissue Sarcoma.
Voss RK; Chiang YJ; Torres KE; Guadagnolo BA; Mann GN; Feig BW; Cormier JN; Roland CL
Ann Surg Oncol; 2017 Oct; 24(11):3271-3278. PubMed ID: 28741122
[TBL] [Abstract][Full Text] [Related]
11. Current stand on systemic therapy in localized soft tissue sarcomas: a clinician's perspective.
Sasi A; Rastogi S
Future Oncol; 2023 Oct; 19(31):2135-2145. PubMed ID: 37860850
[TBL] [Abstract][Full Text] [Related]
12. Worse Survival in Elderly Patients with Extremity Soft-Tissue Sarcoma.
Hoven-Gondrie ML; Bastiaannet E; Ho VK; van Leeuwen BL; Liefers GJ; Hoekstra HJ; Suurmeijer AJ
Ann Surg Oncol; 2016 Aug; 23(8):2577-85. PubMed ID: 26957498
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: Is a Patient's Home Address Associated with Survival Outcomes After Surgery for Extremity and Truncal Soft Tissue Sarcoma?
Lyu HG; Snyder RA; Roland CL
Ann Surg Oncol; 2024 Jun; 31(6):4148-4149. PubMed ID: 38504045
[No Abstract] [Full Text] [Related]
14. Sequential multimodal treatments with chemotherapy and surgery for advanced soft tissue sarcoma may be associated with better survival than chemotherapy.
Chen CT; Chen HW; Lin WH; Huang PM; Lin MW; Yang CY; Hsu CY; Wang CC; Lee JC; Chang K; Huang KH; Chen HM; Chen TW; Yang RS; Hong RL
J Formos Med Assoc; 2024 Mar; ():. PubMed ID: 38521760
[TBL] [Abstract][Full Text] [Related]
15. Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma.
Forker LJ; Bibby B; Yang L; Lane B; Irlam J; Mistry H; Khan M; Valentine H; Wylie J; Shenjere P; Leahy M; Gaunt P; Billingham L; Seddon BM; Grimer R; Robinson M; Choudhury A; West C
Br J Cancer; 2023 Jun; 128(12):2307-2317. PubMed ID: 37085598
[TBL] [Abstract][Full Text] [Related]
16. Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis.
Gorostidi M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Ibañez E; Corrado G; Bartusevicius A; Sukhina O; Zapardiel I;
Ann Surg Oncol; 2023 Nov; 30(12):7645-7652. PubMed ID: 37460742
[TBL] [Abstract][Full Text] [Related]
17. Sarculator: how to improve further prognostication of all sarcomas.
Borghi A; Gronchi A
Curr Opin Oncol; 2024 May; ():. PubMed ID: 38726834
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Braglia L; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
J Clin Oncol; 2020 Jul; 38(19):2178-2186. PubMed ID: 32421444
[TBL] [Abstract][Full Text] [Related]
19. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.
Bonvalot S; Gronchi A; Le Péchoux C; Swallow CJ; Strauss D; Meeus P; van Coevorden F; Stoldt S; Stoeckle E; Rutkowski P; Rastrelli M; Raut CP; Hompes D; De Paoli A; Sangalli C; Honoré C; Chung P; Miah A; Blay JY; Fiore M; Stelmes JJ; Dei Tos AP; Baldini EH; Litière S; Marreaud S; Gelderblom H; Haas RL
Lancet Oncol; 2020 Oct; 21(10):1366-1377. PubMed ID: 32941794
[TBL] [Abstract][Full Text] [Related]
20. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.
Lansu J; Bovée JVMG; Braam P; van Boven H; Flucke U; Bonenkamp JJ; Miah AB; Zaidi SH; Thway K; Bruland ØS; Baldini EH; Jebsen NL; Scholten AN; van den Ende PLA; Krol ADG; Ubbels JF; van der Hage JA; van Werkhoven E; Klomp HM; van der Graaf WTA; van Coevorden F; Schrage Y; van Houdt WJ; Haas RL
JAMA Oncol; 2021 Jan; 7(1):e205865. PubMed ID: 33180100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
